Isis Expects To Submit Its Lipid-Lowering Treatment By Early 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has substantial interest from pharma companies looking to license the drug and expects to start an auction process “very soon,” Isis tells “The Pink Sheet” DAILY.
You may also be interested in...
Antisense Makes Financial Sense: Isis-Ortho-McNeil Pact Worth Potential $400 Mil.
Firms will co-develop up to four investigational drugs for metabolic diseases, including ISIS 325568 and ISIS 377131 for type 2 diabetes.
Antisense Makes Financial Sense: Isis-Ortho-McNeil Pact Worth Potential $400 Mil.
Firms will co-develop up to four investigational drugs for metabolic diseases, including ISIS 325568 and ISIS 377131 for type 2 diabetes.
Isis VP-Corporate Development Kate Winkler Corcoran: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Corcoran discusses firm’s strategy to license and develop specific targets developed through Isis’ proprietary RNA antisense technology.